Status:
COMPLETED
SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University
Collaborating Sponsors:
Jinshazhou Hospital of Guangzhou University of Chinese Medicine
First Affiliated Hospital of Army Military Medical University
Conditions:
Hepatocellular Carcinoma Non-resectable
Eligibility:
All Genders
18-75 years
Brief Summary
This multicenter retrospective study evaluated the efficacy and safety of selective internal radiation therapy (SIRT) combined with lenvatinib and PD-(L)1 inhibitors (SIRT-L-P) versus transarterial ch...
Detailed Description
Consecutive patients with HCC beyond up-to-seven criteria or with PVTT treated with SIRT-L-P or TACE-L-P from June 2022 to October 2024 were screened. Tumor response was evaluated according to modifie...
Eligibility Criteria
Inclusion
- histologically or clinically confirmed diagnosis of HCC at BCLC stage B or C (extrahepatic metastases were allowed)
- Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1
- Child-Pugh class A or B7
- unresectable HCC with intrahepatic tumor beyond up-to-seven criteria and/or with PVTT.
Exclusion
- receipt of other loco-regional therapies, including hepatic arterial infusion chemotherapy, external radiation therapy, or radioactive seed implantation
- Prior systemic therapy
- History of other malignancies
- incomplete medical records
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2025
Estimated Enrollment :
238 Patients enrolled
Trial Details
Trial ID
NCT06916546
Start Date
June 1 2022
End Date
January 31 2025
Last Update
April 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 510260